KEYNOTE-177 Investigators 2022, ' Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177) : final analysis of a randomised, open-label, phase 3 study ', The Lancet Oncology, vol. 23, no. 5, pp. 659-670 . https://doi.org/10.1016/S1470-2045(22)00197-8 Lancet Oncol The Lancet Oncology, 23(5), 659-670. Lancet Publishing Group